European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 139, Issue 2 , Pages 169-175 , August 2008

The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia—A long-term follow-up study

  • Rajesh Varma

      Affiliations

    • Academic Department of Obstetrics and Gynaecology, Birmingham Women's Hospital, Birmingham B15 2TG, UK
    • Corresponding Author InformationCorresponding author at: 2nd floor, Birmingham Women's Hospital, Birmingham B15 2TG, UK. Tel.: +44 121 607 4751; fax: +44 121 607 4795.
    • ,
  • Hemi Soneja

      Affiliations

    • Academic Department of Obstetrics and Gynaecology, Birmingham Women's Hospital, Birmingham B15 2TG, UK
    • ,
  • Kalsang Bhatia

      Affiliations

    • Academic Department of Obstetrics and Gynaecology, Birmingham Women's Hospital, Birmingham B15 2TG, UK
    • ,
  • Raji Ganesan

      Affiliations

    • Department of Histopathology, Birmingham Women's Hospital, Birmingham B15 2TG, UK
    • ,
  • Terence Rollason

      Affiliations

    • Department of Histopathology, Birmingham Women's Hospital, Birmingham B15 2TG, UK
    • ,
  • T. Justin Clark

      Affiliations

    • Academic Department of Obstetrics and Gynaecology, Birmingham Women's Hospital, Birmingham B15 2TG, UK
    • ,
  • Janesh K. Gupta

      Affiliations

    • Academic Department of Obstetrics and Gynaecology, Birmingham Women's Hospital, Birmingham B15 2TG, UK

Received 1 October 2007 ,Revised 14 December 2007 ,Accepted 23 February 2008.

References 

  1. International Society of Gynaecological Pathologists (ISGP), World Health Organisation (WHO). Classification of endometrial hyperplasia. Blaustein's pathology of the female genital tract. 5th ed.. Springer; 2002;pp. 467–500
  2. Fox H, Buckley CH. The endometrial hyperplasias and their relationship to endometrial neoplasia. Histopathology. 1982;6:493–510
  3. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985;56:403–412
  4. Tabata T, Yamawaki T, Yabana T, Ida M, Nishimura K, Nose Y. Natural history of endometrial hyperplasia. Study of 77 patients. Arch Gynecol Obstet. 2001;265:85–88
  5. Terakawa N, Kigawa J, Taketani Y, et al. The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group. J Obstet Gynaecol Res. 1997;23:223–230
  6. Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol. 2006;125(2):259–264
  7. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv. 2004;59(5):368–378
  8. Marsden DE, Hacker NF. Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol. 2001;15(3):393–405
  9. Wildemeersch D, Janssens D, Pylyser K, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas. 2007;57:210–213
  10. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol. 2007;31:988–998
  11. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) – a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol. 2006;125:9–28
  12. Perino A, Quartararo P, Catinella E, Genova G, Cittadini E. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil. 1987;18:137–140
  13. Scarselli G, Tantini C, Colafranceschi M, et al. Levo-norgestrel-nova-T and precancerous lesions of the endometrium. Eur J Gynaecol Oncol. 1988;9:284–286
  14. Vereide AB, Kaino T, Sager G, Arnes M, Orbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol. 2006;101:214–223
  15. Wildemeersch D, Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol. 2003;188:1297–1298
  16. Hejmadi RK, Chaudhri S, Ganesan R, Rollason TP. Morphologic changes in the endometrium associated with the use of the mirena coil: a retrospective study of 106 cases. Int J Surg Pathol. 2007;15:148–154
  17. Horn LC, Meinel A, Handzel R, Einenkel J. Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Ann Diagn Pathol. 2007;11:297–311
  18. Phillips V, Graham CT, Manek S, McCluggage WG. The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology. J Clin Pathol. 2003;56:305–307
  19. Kelly P, Dobbs SP, McCluggage WG. Endometrial hyperplasia involving endometrial polyps: report of a series and discussion of the significance in an endometrial biopsy specimen. BJOG. 2007;114:944–950
  20. Altman DG, Bland JM. Diagnostic tests. 1. Sensitivity and specificity. BMJ. 1994;308:1552
  21. Clark TJ, Mann CH, Shah N, Khan KS, Song F, Gupta JK. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia. Acta Obstet Gynecol Scand. 2001;80:784–793
  22. Garuti G, Cellani F, Garzia D, Colonnelli M, Luerti M. Accuracy of hysteroscopic diagnosis of endometrial hyperplasia: a retrospective study of 323 patients. J Minim Invasive Gynecol. 2005;12:247–253
  23. Gundem G, Sendag F, Kazandi M, et al. Preoperative and postoperative correlation of histopathological findings in cases of endometrial hyperplasia. Eur J Gynaecol Oncol. 2003;24:330–333
  24. Lambert B, Muteganya D, Lepage Y, Boivin Y. Complex hyperplasia of the endometrium. Predictive value of curettage vs. hysterectomy specimens. J Reprod Med. 1994;39:639–642
  25. Jesadapatrakul S, Tangjitgamol S, Manusirivitaya S. Histopathologic consistency between endometrial hyperplasia diagnosis from endometrial curettage and pathologic diagnoses from hysterectomy specimens. J Med Assoc Thai. 2005;88(suppl. 2):S16–S21
  26. Rattanachaiyanont M, Angsuwathana S, Techatrisak K, Tanmahasamut P, Indhavivadhana S, Leerasiri P. Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study. J Obstet Gynaecol Res. 2005;31:98–106
  27. Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer. 2004;14:348–353
  28. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol. 1989;160:126–131
  29. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90:434–440
  30. Perez-Medina T, Bajo J, Folgueira G, Haya J, Ortega P. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. Gynecol Oncol. 1999;73:299–304
  31. Jarvela IY, Santala M. Treatment of non-atypic endometrial hyperplasia using thermal balloon endometrial ablation therapy. Obstet Gynecol Surv. 2005;60:580–582
  32. Agorastos T, Vaitsi V, Pantazis K, Efstathiadis E, Vavilis D, Bontis JN. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2005;118:239–240

PII: S0301-2115(08)00097-3

doi: 10.1016/j.ejogrb.2008.02.022

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 139, Issue 2 , Pages 169-175 , August 2008

Article Tools

* Image Usage & Resolution